Ciltacabtagene autoleucel,Pomalidomide,Bortezomib,Dexamethasone,Daratumumab,lenalidomide
Janssen
['lenalidomide', ' lena', 'cilta-cel', 'cartitude-4', 'cartitude', 'multiple myeloma', 'ciltacabtagene autoleucel']
in the cartitude-4 trial, patients with lenalidomide-refractory multiple myeloma who received ciltacabtagene autoleucel (cilta-cel) had significantly longer progression-free survival than those who received standard therapy. view full results: #asco23 
The New England Journal of Medicine (https://t.co/YGfDrRsIhE) is the world’s leading medical journal and website.